HEARTSCIENCES INC (HSCS)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$3.73+11.01%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · HSCS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 87 industry peers
HSCS — private placement
Dated 2026-08-18
Entry into a Material Definitive Agreement On August 12, 2026, HeartSciences Inc. (the “ Company ” or “ HeartSciences ”) sold and issued to Fortitude Mining Holdings, Inc., a Delaware corporation (“ Fortitude ”), an aggregate of 411,522 shares (the “ Shares ”) of HeartSciences common stock, par value $0.001 per share (the “ Common Stock ”), at a purchase price of $2.43 per Share (the “ Purchase Price ”) in a private placement (the “ PIPE Investment ”). The Purchase Price represented the 30 tr…
Why it matters: Recent equity sales show efforts to get financing. This affects stability and growth.
Worry ifManagement says financing is successful. This helps cash flow and funding.
Less concerning ifMore stock sales or money problems hurt the company's funds.
Why it matters: Lower mining costs could help profits. This supports the merger's value.
Supportive ifFortitude reports a reduction in Zcash mining costs to $40 per coin.
Worry ifFortitude fails to achieve the targeted reduction in mining costs.
Why it matters: Financial results will show if the company is making money or losing it.
Worry ifThe Q3 earnings report will show revenue growth or a big drop in losses.
Less concerning ifQ3 earnings report shows continued losses or no revenue growth.
Why it matters: The earnings report will show if the company is improving and losing less money.
Watch forThe earnings report shows revenue growth or smaller losses compared to past quarters.
Also watch forThe earnings report shows ongoing losses or flat revenue. This means financial struggles continue.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$370 on $10,000 · ±3.7% | How much price usually moves either way. |
| Bad day | $661 loss on $10,000 · 6.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,311 loss on $10,000 · 33.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Filing the proxy statement is a key step toward completing the merger with Fortitude. It signals progress and clarity for shareholders.
Supportive ifThe preliminary proxy statement is filed with the SEC as stated in the press release.
Worry ifThe proxy statement is late. There is no clear communication about it.
Why it matters: Improving revenue is vital for HeartSciences to turn around its financial performance. It shows business traction.
Supportive ifQ2 revenue growth exceeds 15% compared to Q1.
Worry ifQ2 revenue growth remains below 5% compared to Q1.
Why it matters: Getting financing is key for operations. Updates will show if the company can continue.
Worry ifNews of new financing that helps cash flow or lowers debt.
Less concerning ifNo new financing or more equity sales that harm finances.
Why it matters: Cutting losses is key for financial health. It shows better operations and a chance to make money.
Supportive ifOperating losses decrease from $2.54 million in Q4 2026.
Worry ifOperating losses go up or stay the same in future quarters.
Why it matters: Stable leadership is important for the company. Changes can affect performance and trust.
Watch forAnnouncement of a new CEO or stable leadership team for at least three months.
Also watch forMore changes or instability in the leadership team.
Why it matters: Shareholder approval is needed for the merger to go ahead. It shows investor confidence.
Supportive ifShareholders vote in favor of the merger during the special meeting.
Worry ifShareholders did not agree to the merger. This adds more uncertainty for HeartSciences.
Why it matters: The merger could change HeartSciences' growth path. Progress or delays will impact investor confidence.
Supportive ifA press release confirms the merger is done or has made big progress.
Worry ifNews of delays or cancellation of the merger agreement.
Why it matters: M&A activity could change HeartSciences' growth path. A good merger could help finances.
Supportive ifManagement shares news of a good merger with Fortitude Mining.
Worry ifManagement reports delays or problems with the merger.
Why it matters: The earnings release will show how well the company is doing and the merger's effects.
Watch forThe earnings release shows better financial numbers or good news after the merger.
Also watch forThe earnings release shows ongoing losses or bad news that cause worries.
Why it matters: The merger is crucial for HeartSciences' future. It could provide needed resources and stability.
Supportive ifThe merger will close as planned in H2 2026. All regulatory approvals are secured.
Worry ifThe merger may be delayed or fail. This can happen due to regulatory issues or shareholder disapproval.
Why it matters: FDA clearance is key for commercial success. It could boost revenue and credibility.
Supportive ifThe FDA grants 510(k) clearance for the MyoVista wavECG device.
Worry ifThe FDA denies clearance or delays the review process beyond expectations.
Why it matters: A reverse split may be needed to meet Nasdaq listing rules after the merger.
Worry ifThe Board approves a reverse stock split within the range of 1-for-2 to 1-for-5.
Less concerning ifThe Board decides against a reverse stock split or delays the decision.